Pipeline

Robust CAR T CELLS Clinical Pipeline with Near-term Milestones

Aurora’s CAR clinical programs include multiple product candidates in clinical development against a variety of cancer targets in adults and children.

Product Agent Indication Pre-clinical Phase I/IIa Phase I(b)//II(a) Phase II(b)/III FDA Approval
AU105 CART GBM
(Newly Diagnosed)
         
AU101 CART
Intracranial
GBM
(Recurrent)
         
AU101 CART Sarcoma/ Osteosarcoma          
AU101 CART Breast          
AU105 CART Gastric          
AU55 CART Liquid          
AU180 CAR Allogenic          

Completed

Planned

Recurrent Glioblastoma

Phase I/II Recurrent Glioblastoma- AU101 via novel intracranial delivery

Newly Diagnosed Glioblastoma

Phase IIb/III Newly Diagnosed Glioblastoma- AU105 with intravenous infusion

Sarcoma

Phase IIb/III Sarcoma and Osteosarcoma- AU101 via intravenous infusion

Metastatic Breast and Gastric Cancer

Phase II Metastatic Breast and Gastric Cancer with CAR T cells targeting HER2 in combination with checkpoint inhibitor